Skip to main content
Veterinary Medicines

Advantix kožni nanos, raztopina za pse od 25 do 40 kg

Authorised
  • Imidacloprid
  • Permethrin

Product identification

Medicine name:
Advantix kožni nanos, raztopina za pse od 25 do 40 kg
Active substance:
  • Imidacloprid
  • Permethrin
Target species:
  • Dog
Route of administration:
  • Spot-on use

Product details

Active substance and strength:
  • Imidacloprid
    400.00
    milligram(s)
    /
    1.00
    Pipette
  • Permethrin
    2000.00
    milligram(s)
    /
    1.00
    Pipette
Pharmaceutical form:
  • Spot-on solution
Withdrawal period by route of administration:
  • Spot-on use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP53AC54
Authorisation status:
  • Valid
Authorised in:
  • Slovenia
Available in:
  • Slovenia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Elanco Animal Health GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • KVP Pharma+Veterinär Produkte GmbH
Responsible authority:
  • Agency For Medicinal Products And Medical Devices Of The Republic Of Slovenia
Authorisation number:
  • NP/V/0005/004
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Slovenian (PDF)
Published on: 26/01/2024

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Slovenian (PDF)
Published on: 26/01/2024

Labelling

This document does not exist in this language (English). You can find it in another language below.
Slovenian (PDF)
Published on: 26/01/2024
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."